Last reviewed · How we verify
TARTARIC ACID
At a glance
| Generic name | TARTARIC ACID |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1985 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic Characterization of Tartaric Acid in Humans (NA)
- This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are Tolerated (PHASE1)
- Safe and Effective Delivery of Supplemental Iron to Healthy Volunteers (NA)
- Influence of Fluvoxamine on the Pharmacokinetics of BI 409306 (PHASE1)
- Nutritional Stimulation of Growth in Children With Short Stature (NA)
- Study on Gynecological Laparoscopy Under Total Intravenous Anesthesia (NA)
- Safety Tolerability and Pharmacokinetic of BI 409306 (PHASE1)
- Envarsus in Delayed Graft Function (E-DGF) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TARTARIC ACID CI brief — competitive landscape report
- TARTARIC ACID updates RSS · CI watch RSS